ENCOMPASS HEALTH ($EHC) is expected to release its quarterly earnings data on Thursday, April 24th after market close, per Finnhub. Analysts are expecting revenue of $1,445,398,314 and earnings of $1.20 per share.
You can see Quiver Quantitative's $EHC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ENCOMPASS HEALTH Insider Trading Activity
ENCOMPASS HEALTH insiders have traded $EHC stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $EHC stock by insiders over the last 6 months:
- ANDREW L PRICE (Chief Accounting Officer) sold 5,042 shares for an estimated $495,578
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ENCOMPASS HEALTH Hedge Fund Activity
We have seen 278 institutional investors add shares of ENCOMPASS HEALTH stock to their portfolio, and 195 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,656,227 shares (+inf%) to their portfolio in Q4 2024, for an estimated $152,952,563
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 1,441,607 shares (-43.6%) from their portfolio in Q4 2024, for an estimated $133,132,406
- WELLINGTON MANAGEMENT GROUP LLP removed 1,189,732 shares (-22.8%) from their portfolio in Q4 2024, for an estimated $109,871,750
- POINT72 ASSET MANAGEMENT, L.P. removed 869,104 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $80,261,754
- MILLENNIUM MANAGEMENT LLC removed 734,688 shares (-91.7%) from their portfolio in Q4 2024, for an estimated $67,848,436
- JENNISON ASSOCIATES LLC added 564,097 shares (+inf%) to their portfolio in Q4 2024, for an estimated $52,094,357
- BLACKROCK, INC. added 532,705 shares (+5.8%) to their portfolio in Q4 2024, for an estimated $49,195,306
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ENCOMPASS HEALTH Analyst Ratings
Wall Street analysts have issued reports on $EHC in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 10/29/2024
- KeyBanc issued a "Overweight" rating on 10/29/2024
- Barclays issued a "Overweight" rating on 10/29/2024
To track analyst ratings and price targets for ENCOMPASS HEALTH, check out Quiver Quantitative's $EHC forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
